{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:24:28Z","timestamp":1785846268056,"version":"3.56.0"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc."},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Extrapyramidal symptoms (EPS) in association with the long-acting, injectable, atypical antipsychotic aripiprazole once monthly (AOM) have been observed in clinical trials, but information on EPS requiring treatment with anticholinergic drugs in clinical practice is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective of this European post-authorisation safety study (PASS) was to assess the risk of EPS-related events, as defined by dispensings of anticholinergic drugs, linked to the use of AOM in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This European cohort study was based on healthcare databases from Germany (German Pharmacoepidemiological Research Database GePaRD), Italy (Caserta and Palermo healthcare claims databases), and Sweden (National health registers). New users of AOM were followed from their first dispensing for a maximum of 2\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Primary study outcome was an EPS-related event, defined as the first dispensing of an anticholinergic drug. The crude incidence rate (IR) and the cumulative incidence of EPS-related events were estimated. Cox proportional hazard regression modelling was performed to further investigate the effect of potential risk factors for the occurrence of EPS-related events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091748 patients were eligible for inclusion into the primary study populations (Germany\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009629; Italy\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009519; Sweden\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009600). IRs of EPS-related events per 100 patient years were highest in Italy (IR\u2009=\u200918.4; 95% confidence interval (CI) 15.3\u201322.1), followed by Sweden (IR\u2009=\u20097.7; 95% CI 5.8\u201310.2) and Germany (IR\u2009=\u20093.4; 95% CI 2.4\u20134.6). Rates were highest during the first 30\u2009days after treatment initiation. Cumulative incidences after 2\u2009years of treatment were 27.8% (Italy), 11.5% (Sweden), and 10.0% (Germany). Diabetes and previous antipsychotic drug use were identified as risk factors for EPS-related events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this observational study, incidence rates of EPS-related events, defined as the first dispensing of an anticholinergic drug during follow-up, were compatible with the known safety profile of AOM but showed substantial regional variation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>EU PAS number EUPAS21056.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253251368010","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T07:27:47Z","timestamp":1756538867000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3514-9238","authenticated-orcid":false,"given":"Frank","family":"Andersohn","sequence":"first","affiliation":[{"name":"Frank Andersohn Consulting &amp; Research Services, Mandelstr 16, Berlin 10409, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Such","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Valby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jan","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwa","family":"Kalu","sequence":"additional","affiliation":[{"name":"Lundbeck, Deerfield, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"McDonough","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-2574","authenticated-orcid":false,"given":"Jonas","family":"Reinold","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Riedel","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology\u2014BIPS, Bremen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Public Health, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ientile","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tari","sequence":"additional","affiliation":[{"name":"Caserta Local Health Unit, Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pastorello","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Local Health Unit of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Arana","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Forns","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja M.","family":"Hakkarainen","sequence":"additional","affiliation":[{"name":"IQVIA Global Database Studies, M\u00f6lndal, Sweden"},{"name":"Epidemiology &amp; Real-World Science, RWE Scientific Affairs, Parexel International, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Nunez","sequence":"additional","affiliation":[{"name":"IQVIA Global Database Studies, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Tore","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Valby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Simonsen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Valby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Yildirim","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Valby, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257129"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199803003-00009"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370"},{"key":"e_1_3_4_5_2","unstructured":"WHO. Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders https:\/\/cdn.who.int\/media\/docs\/default-source\/mental-health\/mhgap\/psychosis-and-bipolar-disorders\/role-of-anticholinergic-medications-in-patients-requiring-long-term-antipsychotic-treatment-for-psychotic-disorders.pdf?sfvrsn=68417542_0 (2012 accessed 29 September 2024)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2498-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835b091f"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2018.16.4.361"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07530"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.134213"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000543"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_4_13_2","unstructured":"Otsuka Pharmaceutical Netherlands B.V. Abilify Maintena Summary of Product Characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abilify-maintena-epar-product-information_en.pdf (2008 accessed 29 September 2024)."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528030-00002"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381328-2.00009-2"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.11.1521"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.07m03890yel"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200701000-00003"},{"key":"e_1_3_4_19_2","first-page":"15","article-title":"Review of incidence studies of tardive dyskinesia associated with typical antipsychotics","volume":"61","author":"Glazer WM.","year":"2000","unstructured":"Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61(Suppl. 4): 15\u201320.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02191.x"},{"key":"e_1_3_4_21_2","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov Chains based on censored observations","volume":"5","author":"Aalen OO","year":"1978","unstructured":"Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov Chains based on censored observations. Scandinavian J Stat 1978; 5: 141\u2013150.","journal-title":"Scandinavian J Stat"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.06.003"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1113"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796015000694"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.05.033"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.03.003"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253251368010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253251368010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253251368010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:53:40Z","timestamp":1777593220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253251368010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"alternative-id":["10.1177\/20451253251368010"],"URL":"https:\/\/doi.org\/10.1177\/20451253251368010","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"20451253251368010"}}